Mini-review: Hemostasis Pathophysiology Associated With Increased Risk of Thrombosis in Acute COVID-19 Infection
Jamie Gillan, Jamie-lee Brundyn, Indu Singh
Int. J. Bio. Lab. Sci 2022(11)1:18-22【PDF】
The aim of this mini review is to understand how COVID-19 contributes to thrombotic events in patients. The recent and ongoing coronavirus 19 pandemic (COVID-19) has presented tremendous challenges to healthcare, with approximately 219 million cases worldwide and 4.5 million deaths associated with infection to date. Patients experience a significant immunological response to the virus, and this is often followed by a state of acute respiratory distress syndrome (ARDS). It has become increasingly evident that hemostatic dysregulation and thrombotic events are prevalent complications of acute COVID-19 infection and may persist chronically in the manifestation of “long-COVID.” Current anticoagulant therapies are insufficient in mitigating the risk of thrombosis in COVID-19 patients and further understanding regarding the pathophysiological mechanisms of hemostatic dysregulation following COVID-19 infection is critical to improve clinical management. This manuscript endeavors to summarize the current understanding based on the recent clinical literature and to identify potential future research directions to best inform clinicians on how to optimize patient outcomes.
Key words: COVID-19, hemostasis, thrombosis